BrightSpring Q2 Beat Drives Another Guidance Raise, but Cost and Overhang Risks Linger

What happened

BrightSpring Health Services reported strong second-quarter 2026 results, prompting management to raise full-year revenue and adjusted EBITDA guidance for the second time this year. The upgrade was driven by continued momentum in specialty and infusion pharmacy, which offset ongoing script volume declines and Inflation Reduction Act pressure on the Home & Community Pharmacy unit. Provider Services also contributed, with home health average daily census sustaining robust growth, though Q1’s surge in Pharmacy Solutions SG&A remains a concern. The company exited the quarter with ample liquidity, but the stock still trades at a demanding 26x EV/EBITDA based on the raised outlook. While near-term execution looks solid, the thesis requires script stabilization and cost moderation before a meaningful re-rating can occur.

Implication

Investors should focus on the next quarterly report for signs that pharmacy script declines are halting and that public-company costs are not becoming a permanent margin ceiling. If the raised trajectory is maintained and sponsors avoid new large secondary offerings, the stock could drift toward the low $70s, though a pullback to the $55-$60 range would offer a more attractive risk/reward entry.

Thesis delta

BrightSpring’s Q2 guidance increase strengthens the near-term bullish case by showing that specialty/infusion mix can sustain earnings momentum even with modest script softness. However, the core concerns—structurally higher SG&A and residual sponsor overhang—remain, so the investment thesis stays neutral until cost growth moderates and volume trends turn positive.